of the incidence of SM among 2658 patients with localized prostate cancer after definitive treatment with radical prostatectomy, EBRT or BT [8]. Of the 413 patients treated with BT, 166 were aged <65 years. The 10-year SM-free survival for the whole BT-treated group was 87%, which was not significantly different from that of the cohort treated with radical prostatectomy (P = 0.37), Their multivariate analysis suggested that older age (P = 0.01) and history of smoking (P < 0.001) were significant predictors for the development of an SM, whereas treatment intervention was not a significant variable.Our group have recently presented data on 76 patients under the age of 55 with localized prostate cancer treated with BT-based regimens [2]. The actuarial 8-year PSA-free survival was 96%. Among the 54 patients with preoperative International Index of Erectile Function (IIEF) data available, 81% were potent (IIEF score Յ11) before receiving treatment. At 4-year follow-up, 94% of these patients with IIEF data available were still potent. BT is a convenient, effective and well-tolerated treatment for low-and intermediate-risk clinically localized prostate cancer in men aged Յ60 years, which often preserves erectile function. BT may be considered one of the treatments of choice for these younger patients. after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
Conflict of Interest